Cochrane review: Anti-amyloid Alzheimer’s drugs show no meaningful clinical benefit

An influential independent review has concluded that drugs designed to clear beta-amyloid from the brain do not deliver a meaningful clinical benefit for people with Alzheimer’s disease and carry safety risks, including increased rates of brain bleeding and swelling.

The analysis, published Thursday by Cochrane, assessed medicines that target beta-amyloid proteins, which aggregate into plaques commonly found in the brains of people with Alzheimer’s. Because these proteins can be detected before symptoms appear, researchers long hypothesized that removing them could slow or prevent the disease.

Early trials hinted at promise, but subsequent studies have not borne that out, the reviewers found. “Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy, in a statement.

The review synthesized results from 17 clinical trials involving 20,342 participants. According to Nonino and his co-authors, the totality of evidence indicates that further trials of amyloid-clearing strategies are unlikely to benefit patients, and they recommend shifting resources toward alternative approaches.

One emerging line of inquiry highlighted by the authors examines the role of inflammation, including that associated with lifestyle factors, as a potential driver of Alzheimer’s. A growing body of research cited by the review suggests links between systemic inflammation and cognitive decline.

The findings add weight to calls for a broader rethinking of Alzheimer’s drug development. While the disease remains without a cure, the reviewers argue that redirecting efforts toward other biological pathways may offer more promising avenues for future therapies.